NCT02971761View on ClinicalTrials.gov

Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

June 1, 2017

Primary Completion Date

October 28, 2020

Study Completion Date

August 16, 2022

Conditions
Androgen Receptor PositiveEstrogen Receptor NegativeHER2/Neu NegativeMetastatic Triple-Negative Breast CarcinomaProgesterone Receptor NegativeStage IV Breast Cancer AJCC v6 and v7
Interventions
DRUG

Enobosarm

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Pembrolizumab

Given IV

Trial Locations (7)

91010

City of Hope Medical Center, Duarte

91030

City of Hope South Pasadena, South Pasadena

91345

City of Hope Mission Hills, Mission Hills

91730

City of Hope Rancho Cucamonga, Rancho Cucamonga

91790

City of Hope West Covina, West Covina

92879

City of Hope Corona, Corona

93534

City of Hope Antelope Valley, Lancaster

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER

NCT02971761 - Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer | Biotech Hunter | Biotech Hunter